The primary goal of this observational study is to learn about postpartum pulmonary artery
pressure in women who suffered from Preeclampsia and Antiphospholipid Syndrome.
The main question it aims to answer is whether the conjunction of preeclampsia with obstetric
antiphospholipid syndrome significantly foster the development of long-lasting pulmonary
Only participants who suffered from preeclampsia during pregnancy will be followed for a
period up to 3 years postpartum. Researchers will compare women with or without obstetric
This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy
for the treatment pulmonary hypertension.
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and
tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term
and long-term safety and tolerability of L606 in this patient population; also evaluate the
steady-state pharmacokinetics (PK) of L606 as compared to Tyvaso, effects on exercise
ability, quality of life, and treatment satisfaction with L606.
The study is aimed to observe the efficacy and safety of Nitric Oxide Generator and Delivery
System in Pulmonary Hypertension of Newborn in real clinical settings.
Arrhythmias are considered a prominent phenomenon in pulmonary hypertension (PH) as the
disease progresses. According primarily to retrospective studies with up to 24 hours of
monitoring, supraventricular tachycardias (SVT) can be found in 8-35% of patients, with
significant impact on survival.
Furthermore, a few prospective studies to date deploying short-term monitoring (10 minutes-24
hours) have revealed lower heart rate variability (HRV) in patients with pulmonary arterial
In ASPIRE arrhythmias and heart rate variability is being assessed via long term monitoring.
Currently the the loop-recorder...
Pulmonary hypertension represents a challenging and heterogeneous condition that is
associated with high mortality and morbidity if left untreated. Artificial intelligence is
used to study and develop theories and methods that simulate and extend human intelligence,
which is being applied in fields related to cardiovascular diseases. The study intends to
combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai
Hospital with artificial intelligence techniques to create programs that can screen and
diagnose pulmonary hypertension.
The study aim is to monitor, during exercise tests carried out in various conditions, the
alveolar dead space, by means of continuous transcutaneous measurement of Pt CO2, which would
be used as a surrogate for arterial PaCO2. Validity of this measurement needs to be assessed
against arterial sampling (either arterial, or arterialized capillary), especially with
regards to the lag time required by the CO2 diffusion from the arterial compartment (PaCO2)
to the cutaneous one (PtCO2), in particular when rapid changes of CO2 might be induced by
The evaluation will be done in 2 different settings:
- intensive care...
Chronic thromboembolic pulmonary hypertension [CTEPH] is caused by pulmonary emboli that have
enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients
with CTEPH are treated with balloon pulmonary angioplasty [BPA] which mechanically opens the
narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary
surface area [FCSA] is recovered during BPA. We plan to measure FCSAIn CTEPH patients, before
and after a session of BPA.
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of
ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or
PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
The primary objective of this study is to assess the effect of early and rapid treprostinil
therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV)
function and reverse RV remodeling in participants with pulmonary arterial hypertension